Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Agenus Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its immuno-oncology products, botensilimab and balstilimab, during the class period from January 23, 2023, to July 17, 2024 [1][2]. Group 1 - The class action alleges that the combination therapy of botensilimab and balstilimab was less effective than represented, leading to overstated clinical results and regulatory prospects [1]. - Shareholders who purchased shares during the specified class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment, which is not required for recovery [1]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is November 5, 2024 [2]. Group 2 - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Agenus Inc. regarding a class action lawsuit due to alleged misleading statements about the effectiveness of their immuno-oncology products [1][2]. Group 1: Allegations - The complaint alleges that during the class period from January 23, 2023, to July 17, 2024, the defendants made materially false and misleading statements about the combination therapy of botensilimab and balstilimab [2]. - It is claimed that the effectiveness of the combination therapy was overstated, leading to inflated clinical results and regulatory and commercial prospects [2]. - As a result, the company's public statements were deemed materially false and misleading throughout the relevant period [2]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is November 5, 2024, and participation does not require appointment as a lead plaintiff [2]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates on the case [2]. - The Gross Law Firm emphasizes that there is no cost or obligation for shareholders to participate in the case [2].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Agenus To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Agenus between January 23, 2023 and July 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 16, 2024 (GLOBE NEWS ...

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against Agenus Inc. for allegedly issuing false and misleading statements regarding the effectiveness of its immuno-oncology products, botensilimab and balstilimab, during the class period from January 23, 2023, to July 17, 2024 [1]. Group 1 - The class action alleges that the combination therapy of botensilimab and balstilimab was less effective than what was communicated to investors [1]. - The complaint states that the clinical results and regulatory and commercial prospects of botensilimab and balstilimab were overstated [1]. - As a result of these misleading statements, the company's public disclosures were deemed materially false and misleading throughout the relevant period [1]. Group 2 - Shareholders who purchased shares of Agenus during the specified class period are encouraged to register for the class action, with a deadline of November 5, 2024, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's progress [2]. - Participation in the case incurs no cost or obligation for the shareholders [2].

NEW YORK, Oct. 10, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=107506&from=4 CLASS PERIOD: January 23, 2023 to July 17, 2024 ...

Core Viewpoint - A class action securities lawsuit has been filed against Agenus Inc. for alleged securities fraud affecting investors between January 23, 2023, and July 17, 2024 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Agenus made false statements regarding the effectiveness of its immuno-oncology combination therapy products, botensilimab and balstilimab, which were overstated [2] - It is alleged that the clinical results and regulatory prospects of these products were misrepresented, leading to materially false and misleading public statements [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 5, 2024, to request appointment as lead plaintiff, although participation in any recovery does not require this [2] - Class members may be entitled to compensation without any out-of-pocket costs or fees [2] Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [3] - The firm has over 70 employees dedicated to serving clients in complex securities litigation [3]

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN). Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=107034&from=3  CLASS PERIOD: January 23, 2023 to July ...

NEW YORK, Oct. 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=106639&from=4 CLASS PERIOD: January 23, 2023 to July 17, 2024A ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Agenus Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the Agenus securities is from January 23, 2023, to July 17, 2024, and the lead plaintiff deadline is November 5, 2024 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [1][4] Group 2: Case Allegations - The lawsuit alleges that Agenus made false and misleading statements regarding the effectiveness of its combination therapy involving botensilimab and balstilimab [3] - It is claimed that the clinical results and regulatory prospects of these therapies were overstated, leading to materially false public statements by Agenus [3] - The lawsuit asserts that investors suffered damages when the true details about the therapies were revealed [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [2] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [2] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [2]

Core Viewpoint - A class action has been filed against Agenus Inc. for allegedly misleading investors about the effectiveness and prospects of its drug candidates, particularly botensilimab and balstilimab, during the specified class period [1][2]. Group 1: Company Overview - Agenus Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology products, including balstilimab, an anti-PD-1 antagonist, and botensilimab, a CTLA-4 blocking antibody [1]. - The company is currently conducting Phase 2 clinical trials for both drug candidates, targeting second line cervical cancer and pancreatic cancer/melanoma, respectively [1]. Group 2: Allegations and Legal Action - The class action alleges that Agenus failed to disclose that the combination therapy of botensilimab and balstilimab was less effective than represented, leading to overstated clinical results and regulatory prospects [2]. - Following a press release on July 18, 2024, regarding an FDA meeting, Agenus's stock price dropped by $10.43 per share, or 58.83%, closing at $7.30 per share, after the FDA advised against submission for Accelerated Approval due to concerns over survival benefits [3]. Group 3: Next Steps for Shareholders - Shareholders interested in participating in the class action must submit their application to serve as lead plaintiff by November 5, 2024 [4]. - Shareholders can choose to remain absent class members without participating in the case while still being eligible for recovery [4].